ClinicalTrials.gov
public full text
Public Domain
Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)
This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis#1212964
- Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs#911175
- Magnesium and Metabolic Syndrome#67727
- The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects#869638
- Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis#272259
Record · ID 1375322
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive